Literature DB >> 28772017

An initiative to improve primary prevention of cardiovascular disease in adults with type II diabetes based on the ACC/AHA (2013) and ADA (2016) guidelines.

Litzie Garza1, Jean Dols1, Maria Gillespie1.   

Abstract

PURPOSE: This project was designed to increase family practice clinicians' adherence to the American College of Cardiology/American Heart Association (2013) and American Diabetes Association (ADA, 2016) clinical practice guidelines for the prevention of cardiovascular disease (CVD) in 40- to 75-year-old adults with type II diabetes (DMII) through interactive education, an electronic alert, and quality improvement sessions on the treatment and management of cholesterol in a family practice primary care setting. DATA SOURCES: A pre- and postretrospective chart review of 159 charts from a family practice clinic was conducted. Included in the chart review were 40- to 75-year-olds with a diagnosis of DMII.
CONCLUSIONS: Three outcomes were analyzed. Assessment of Atherosclerotic Cardiovascular Disease risk score increased from 0% to 76.7% (X2 (1, 159) = 93.46, p < .001), diet and exercise counseling documentation increased from 85% to 100%, and statin therapy application increased from 55.1% to 72.2% (X2 (1, 159) = 11.55, p = .003) in eligible adults 40-75 years-old with DMII. IMPLICATIONS FOR PRACTICE: This initiative helps to build the body of evidence regarding useful interventions to improve primary prevention of CVD by improving clinician adherence to the clinical care guidelines for 40- to 75-year-old adults with DMII. ©2017 American Association of Nurse Practitioners.

Entities:  

Keywords:  Nurse practitioners; advanced practice nursing; cardiovascular disease; evidence-based practice; family practice; patient education; primary prevention; type II diabetes

Mesh:

Year:  2017        PMID: 28772017     DOI: 10.1002/2327-6924.12492

Source DB:  PubMed          Journal:  J Am Assoc Nurse Pract        ISSN: 2327-6886            Impact factor:   1.165


  4 in total

1.  Adipose tissue-derived WNT5A regulates vascular redox signaling in obesity via USP17/RAC1-mediated activation of NADPH oxidases.

Authors:  Ioannis Akoumianakis; Fabio Sanna; Marios Margaritis; Ileana Badi; Nadia Akawi; Laura Herdman; Patricia Coutinho; Harry Fagan; Alexios S Antonopoulos; Evangelos K Oikonomou; Sheena Thomas; Amy P Chiu; Surawee Chuaiphichai; Christos P Kotanidis; Constantinos Christodoulides; Mario Petrou; George Krasopoulos; Rana Sayeed; Lei Lv; Ashley Hale; Meisam Naeimi Kararoudi; Eileen McNeill; Gillian Douglas; Sarah George; Dimitris Tousoulis; Keith M Channon; Charalambos Antoniades
Journal:  Sci Transl Med       Date:  2019-09-18       Impact factor: 17.956

2.  Attainment of recommended therapeutic targets of modifiable cardiovascular risk factors among individuals with type 2 diabetes mellitus screened at a diabetes clinic in Sri Lanka.

Authors:  Thilak Priyantha Weerarathna; Herath Mudiyanselage Meththananda Herath; Gayani Liyanage; Miyuru Kavinda Weerarathna; Vidarsha Senadheera
Journal:  Diabetes Metab Syndr Obes       Date:  2018-08-08       Impact factor: 3.168

3.  Association of Self-Reported Dietary and Drug Compliance with Optimal Metabolic Control in Patients with Type 2 Diabetes: Clinic-Based Single-Center Study in a Developing Country.

Authors:  Thilak Priyantha Weerarathna; Miyuru Kavinda Weerarathna; Vidarsha Senadheera; Herath Mudiyanselage Meththananda Herath; Gayani Liyanage
Journal:  J Nutr Metab       Date:  2018-07-24

4.  Effects of canagliflozin on human myocardial redox signalling: clinical implications.

Authors:  Hidekazu Kondo; Ioannis Akoumianakis; Ileana Badi; Nadia Akawi; Christos P Kotanidis; Murray Polkinghorne; Ilaria Stadiotti; Elena Sommariva; Alexios S Antonopoulos; Maria C Carena; Evangelos K Oikonomou; Elsa Mauricio Reus; Rana Sayeed; George Krasopoulos; Vivek Srivastava; Shakil Farid; Surawee Chuaiphichai; Cheerag Shirodaria; Keith M Channon; Barbara Casadei; Charalambos Antoniades
Journal:  Eur Heart J       Date:  2021-12-21       Impact factor: 35.855

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.